Literature DB >> 19073710

Alpha 1 antitrypsin activity is decreased in human amnion in premature rupture of the fetal membranes.

Noriko Izumi-Yoneda1, Ayaka Toda, Motonori Okabe, Chika Koike, Seiji Takashima, Toshiko Yoshida, Ikuo Konishi, Shigeru Saito, Toshio Nikaido.   

Abstract

Preterm premature rupture of the membranes (PPROM) has been considered to be closely associated with chorioamnionitis. However, the detailed mechanism is not well understood. Alpha 1 antitrypsin (AAT) was reported to decrease in concentration in amniotic fluid obtained from patients with PPROM. However, the origin of AAT in amniotic fluid has not been clarified. In this study, we assessed the expression and localization of AAT in human amnion, as well as its biological activity in cases with PROM. Human amniotic epithelial (hAE) cells expressed AAT. After stimulation with oncostatin M (OSM), interleukin-6 (IL-6) or tumor necrotic factor alpha (TNF alpha), hAE cells increased the expression of AAT, while the expression of MMP9 was reduced by OSM and induced by TNF alpha. Oxidized AAT (inactivated form) was detected in the amnion with PPROM and TPROM, but not in specimens without PROM. Moreover, AAT activity was decreased in amnions from cases with PROM, regardless of gestational age. Thus, the results showed that AAT in the amnion may function as a protective shield at inflammatory sites, and not as it loses it inhibitory activity in cases with PROM, possibly by oxidation, suggesting that its imbalance contributes to PROM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19073710     DOI: 10.1093/molehr/gan071

Source DB:  PubMed          Journal:  Mol Hum Reprod        ISSN: 1360-9947            Impact factor:   4.025


  6 in total

1.  Characterization of amniotic stem cells.

Authors:  Chika Koike; Kaixuan Zhou; Yuji Takeda; Moustafa Fathy; Motonori Okabe; Toshiko Yoshida; Yukio Nakamura; Yukio Kato; Toshio Nikaido
Journal:  Cell Reprogram       Date:  2014-08       Impact factor: 1.987

Review 2.  Expanding the clinical indications for α(1)-antitrypsin therapy.

Authors:  Eli C Lewis
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

3.  Oxidized alpha-1 antitrypsin as a predictive risk marker of opisthorchiasis-associated cholangiocarcinoma.

Authors:  Wassana Jamnongkan; Anchalee Techasen; Raynoo Thanan; Kunyarat Duenngai; Paiboon Sithithaworn; Eimorn Mairiang; Watcharin Loilome; Nisana Namwat; Chawalit Pairojkul; Puangrat Yongvanit
Journal:  Tumour Biol       Date:  2012-11-28

4.  Transcriptome landscape of the human placenta.

Authors:  Jinsil Kim; Keyan Zhao; Peng Jiang; Zhi-xiang Lu; Jinkai Wang; Jeffrey C Murray; Yi Xing
Journal:  BMC Genomics       Date:  2012-03-27       Impact factor: 3.969

Review 5.  Post-Translational Modifications of Circulating Alpha-1-Antitrypsin Protein.

Authors:  Urszula Lechowicz; Stefan Rudzinski; Aleksandra Jezela-Stanek; Sabina Janciauskiene; Joanna Chorostowska-Wynimko
Journal:  Int J Mol Sci       Date:  2020-12-02       Impact factor: 5.923

Review 6.  T Helper Subsets, Peripheral Plasticity, and the Acute Phase Protein, α1-Antitrypsin.

Authors:  Boris M Baranovski; Gabriella S Freixo-Lima; Eli C Lewis; Peleg Rider
Journal:  Biomed Res Int       Date:  2015-10-25       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.